Overview. Analytical method transfer demonstrates that a receiving laboratory can perform an established procedure and produce results consistent with the method's intended use. In cannabis testing, transfer risk is increased by botanical heterogeneity, matrix-sensitive extraction, low-level contaminant limits and differences in instrument configuration.
Choose the transfer strategy
The transfer may use comparative testing, co-validation, partial revalidation or a justified waiver. The strategy should reflect method maturity, receiving-laboratory experience, matrix complexity and differences in technology.
Assess laboratory differences
Columns, detectors, software, autosamplers, sample-preparation tools, reference standards and environmental conditions can all affect performance. These differences should be documented before the protocol is approved.
Transfer potency methods
Cannabinoid assays should address acidic and neutral forms, total-cannabinoid calculations, extraction recovery and peak resolution. Representative flower, oil and extract samples should be selected where the method covers multiple matrices.
Transfer contaminant methods
Pesticide, mycotoxin, residual-solvent and elemental-impurity methods often operate close to reporting limits. Transfer acceptance should therefore consider recovery, sensitivity, blank performance and matrix effect.
Training and knowledge transfer
The sending laboratory should communicate critical development knowledge, known failure modes and data-processing rules. Method transfer is not only an inter-laboratory comparison exercise.
Protocol and acceptance criteria
The protocol should define samples, replicates, analysts, sequence design, statistical approach, deviations and acceptance criteria. Criteria should be set before data generation.
Closure and routine deployment
Transfer is complete only after discrepancies are resolved, the report is approved, analysts are trained and the receiving laboratory has placed the method under routine governance.
Practical reference table
| Transfer element | Cannabis-specific concern | Evidence |
|---|---|---|
| Sample selection | Matrix and batch variability | Representative flower/oil/extract set |
| Extraction | Recovery differences | Comparative recovery data |
| Chromatography | Peak resolution and integration | System suitability and reviewed chromatograms |
| Sensitivity | Low pesticide or solvent limits | LOQ and control sample performance |
| Data processing | Total THC/CBD calculations | Controlled formula and audit trail |
Control and decision path
Frequently asked questions
Does every transfer require full comparative testing?
No. The approach depends on method maturity, risk and receiving-laboratory capability.
What samples should be used?
Samples should challenge the method across relevant matrices, ranges and known risks.
Can a contract laboratory waive transfer?
Only with a documented scientific justification and adequate existing evidence.
What happens if results differ between laboratories?
The cause should be investigated across sample preparation, equipment, standards, calculations and method execution.
When is partial revalidation required?
When differences in technology, matrix or operating range affect selected performance characteristics.
Primary references and guidance
- USP <1224>, Transfer of Analytical Procedures
- ICH Q2(R2)
- ICH Q14
- EU GMP Part I, Chapter 6
- ISO 17025
- EU GMP Chapter 7
- PIC/S PE 009
- GAMP 5 where data systems differ
Confirm the current effective revision and national applicability before operational or regulatory use.